Gasperini C - Search Results

1

Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.

Lazzarino G, Amorini AM, Petzold A, Gasperini C, Ruggieri S, Quartuccio ME, Lazzarino G, Di Stasio E, Tavazzi B. Lazzarino G, et al. Among authors: gasperini c. Mol Neurobiol. 2017 Nov;54(9):7520-7533. doi: 10.1007/s12035-016-0257-9. Epub 2016 Nov 8. Mol Neurobiol. 2017. PMID: 27826747

2

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C, Antonelli G, Bastianello S, Pozzilli C. Tomassini V, et al. Among authors: gasperini c. J Neurol. 2006 Mar;253(3):287-93. doi: 10.1007/s00415-005-0979-5. Epub 2005 Sep 14. J Neurol. 2006. PMID: 16151600 Clinical Trial.

3

New oral drugs for multiple sclerosis.

Gasperini C, Ruggieri S. Gasperini C, et al. Neurol Sci. 2009 Oct;30 Suppl 2:S179-83. doi: 10.1007/s10072-009-0146-3. Neurol Sci. 2009. PMID: 19882371 Review.

4

The prevalence of multiple sclerosis in central Italy.

Millefiorini E, Cortese A, Di Rezze S, Barletta G, Bellantonio P, Batocchi AP, Di Battista G, Fiore S, Gasperini C, Grasso MG, Koudriatseva T, Totaro R, Durastanti V. Millefiorini E, et al. Among authors: gasperini c. Mult Scler. 2010 Dec;16(12):1432-6. doi: 10.1177/1352458510373263. Epub 2010 Sep 10. Mult Scler. 2010. PMID: 20834041

5

Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.

Gasperini C, Ruggieri S, Pozzilli C. Gasperini C, et al. Ther Clin Risk Manag. 2010 Sep 7;6:391-9. doi: 10.2147/tcrm.s6639. Ther Clin Risk Manag. 2010. PMID: 20856685 Free PMC article.

6

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group. Comi G, et al. Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316. Ann Neurol. 2011. PMID: 21280077 Clinical Trial.

7

Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis: a cross-sectional and longitudinal fMRI study.

Pantano P, Bernardi S, Tinelli E, Pontecorvo S, Lenzi D, Raz E, Tona F, Gasperini C, Pozzilli C. Pantano P, et al. Among authors: gasperini c. Mult Scler. 2011 Oct;17(10):1177-84. doi: 10.1177/1352458511411757. Epub 2011 Jun 15. Mult Scler. 2011. PMID: 21677022

8

Emerging oral drugs for relapsing-remitting multiple sclerosis.

Gasperini C, Ruggieri S. Gasperini C, et al. Expert Opin Emerg Drugs. 2011 Dec;16(4):697-712. doi: 10.1517/14728214.2011.642861. Epub 2011 Dec 7. Expert Opin Emerg Drugs. 2011. PMID: 22148963 Review.

9

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.

Gasperini C, Ruggieri S. Gasperini C, et al. Drug Des Devel Ther. 2012;6:175-86. doi: 10.2147/DDDT.S8927. Epub 2012 Jul 19. Drug Des Devel Ther. 2012. PMID: 22888218 Free PMC article. Review.

10

Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod.

Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C. Gasperini C, et al. Ther Clin Risk Manag. 2013;9:73-85. doi: 10.2147/TCRM.S17426. Epub 2013 Mar 3. Ther Clin Risk Manag. 2013. PMID: 23483794 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters